Ilynn Bulatao

6PUBLICATIONS
73CO-AUTHORS
Toxicology (incl. clinical toxicology)Cancer therapy (excl. chemotherapy and radiation therapy)PharmacogenomicsMolecular targetsEnvironmental epidemiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Aug 07, 2026
Adverse Reactions Identified after Approval of Novel Medicines: Analysis of 339 New Molecular Entities and Therapeutic Biologics.

|Aug 11, 2025
US Food and Drug Administration Approval Summary: Ribociclib With an Aromatase Inhibitor in the Adjuvant Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Stage II and III High-Risk Early Breast Cancer Treatment Setting.

Jennifer J Gao, Tatiana M Prowell, Haley Gittleman

|Jul 17, 2025
FDA Approval Summary: Niraparib plus Abiraterone Acetate Fixed-Dose Combination for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer.

William F Maguire, Dow-Chung Chi, Sundeep Agrawal

|May 09, 2025
Cardiac Adverse Events in Patients Receiving Immune Checkpoint Inhibitors in the Adjuvant Setting: An FDA Pooled Analysis.

Asma Dilawari, Mori J Krantz, Ilynn Bulatao

|Jan 14, 2025
FDA Approval Summary: Tovorafenib for Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma.

Sonia Singh, Diana Bradford, Somak Chatterjee

|Feb 21, 2024
US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer.

Mirat Shah, Hima Lingam, Xin Gao

Pageof 1

Frequent Collaborators

4 joint publications

Shenghui Tang

3 joint publications

William F Pierce

3 joint publications

Laleh Amiri-Kordestani

3 joint publications

Richard Pazdur